CTA
ALNY icon

Carillon Tower Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Carillon Tower Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$26.2M Buy
+201,572
New +$26.9M 0.16% 192
2020
Q3 		– Sell
-201,572
Closed -$29.9M – 438
2020
Q2 		$29.9M Buy
+201,572
New +$27.2M 0.23% 137

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Carillon Tower Advisers's ALNY Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2020: 201,572 shares worth $26.2M. The stake represents 0.16% of the portfolio and ranks #192 among its holdings. This is a return to the name: Carillon Tower Advisers previously reported a position in ALNY as recently as Q2 2020.

Carillon Tower Advisers first reported a position in ALNY in Q2 2020 and has held it in 2 quarters since. The position peaked at $29.9M in Q2 2020. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Carillon Tower Advisers held 201,572 shares of Alnylam Pharmaceuticals worth $26.2M as of Q4 2020.
  • Alnylam Pharmaceuticals was a new Carillon Tower Advisers position in Q4 2020.
  • Alnylam Pharmaceuticals made up 0.16% of Carillon Tower Advisers's portfolio in Q4 2020, its #192 holding.
  • Carillon Tower Advisers first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • Carillon Tower Advisers's Alnylam Pharmaceuticals position peaked at $29.9M in Q2 2020.
  • 376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.